Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carsten Buhmann

Showing results (51-60 of 118) with videos related to

Pageof 12
Sort By:
Parkinsonism & Related Disorders|November 12, 2018
Is the Munich dysphagia Test-Parkinson's disease (MDT-PD) a valid screening tool for patients at risk for aspiration?Carsten Buhmann, Till Flügel, Moritz Bihler, et al.
Movement Disorders Clinical Practice|January 21, 2025
Mood Lability Induced by Pallidal Deep Brain Stimulation in a Patient with Meige SyndromeKai Grimm, Alessandro Gulberti, Wolfgang Hamel, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|January 24, 2022
Serum neurofilament light chain and postural instability/gait difficulty (PIGD) subtypes of Parkinson's disease in the MARK-PD studyMonika Pötter-Nerger, Janina Dutke, Susanne Lezius, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|August 9, 2015
Wearable sensor-based objective assessment of motor symptoms in Parkinson's diseaseChristiana Ossig, Angelo Antonini, Carsten Buhmann, et al.
Neurobiology of Disease|January 31, 2004
Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influenced by antiparkinsonian medicationCarsten Buhmann, Sönke Arlt, Anatol Kontush, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 17, 2020
Reply to: "N-Terminal Pro-B-Type Natriuretic Peptide Levels in Parkinson's Disease"Chi-Un Choe, Elina Petersen, Monika Pötter-Nerger, et al.
Neurogastroenterology and Motility|December 15, 2018
Predictive clinical factors for penetration and aspiration in Parkinson's diseaseJulie Cläre Nienstedt, Moritz Bihler, Almut Niessen, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|August 19, 2024
Clinicians' viewpoints on current paradigms of care and research in Parkinson's diseaseThomas Müller, Carsten Buhmann, Martin Delf, et al.
Der Nervenarzt|January 19, 2022
[Relevance of COMT inhibitors in the treatment of motor fluctuations]Wolfgang H Jost, Carsten Buhmann, Joseph Classen, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 17, 2006
MEP latency shift after implantation of deep brain stimulation systems in the subthalamic nucleus in patients with advanced Parkinson's diseaseUte Hidding, Tobias Bäumer, Hartwig Roman Siebner, et al.
Pageof 12

Showing results (51-60 of 118) with videos related to

Sort By:
Pageof 12
Parkinsonism & Related Disorders|November 12, 2018
Is the Munich dysphagia Test-Parkinson's disease (MDT-PD) a valid screening tool for patients at risk for aspiration?Carsten Buhmann, Till Flügel, Moritz Bihler, et al.
Movement Disorders Clinical Practice|January 21, 2025
Mood Lability Induced by Pallidal Deep Brain Stimulation in a Patient with Meige SyndromeKai Grimm, Alessandro Gulberti, Wolfgang Hamel, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|January 24, 2022
Serum neurofilament light chain and postural instability/gait difficulty (PIGD) subtypes of Parkinson's disease in the MARK-PD studyMonika Pötter-Nerger, Janina Dutke, Susanne Lezius, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|August 9, 2015
Wearable sensor-based objective assessment of motor symptoms in Parkinson's diseaseChristiana Ossig, Angelo Antonini, Carsten Buhmann, et al.
Neurobiology of Disease|January 31, 2004
Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influenced by antiparkinsonian medicationCarsten Buhmann, Sönke Arlt, Anatol Kontush, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 17, 2020
Reply to: "N-Terminal Pro-B-Type Natriuretic Peptide Levels in Parkinson's Disease"Chi-Un Choe, Elina Petersen, Monika Pötter-Nerger, et al.
Neurogastroenterology and Motility|December 15, 2018
Predictive clinical factors for penetration and aspiration in Parkinson's diseaseJulie Cläre Nienstedt, Moritz Bihler, Almut Niessen, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|August 19, 2024
Clinicians' viewpoints on current paradigms of care and research in Parkinson's diseaseThomas Müller, Carsten Buhmann, Martin Delf, et al.
Der Nervenarzt|January 19, 2022
[Relevance of COMT inhibitors in the treatment of motor fluctuations]Wolfgang H Jost, Carsten Buhmann, Joseph Classen, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 17, 2006
MEP latency shift after implantation of deep brain stimulation systems in the subthalamic nucleus in patients with advanced Parkinson's diseaseUte Hidding, Tobias Bäumer, Hartwig Roman Siebner, et al.
Pageof 12